273 related articles for article (PubMed ID: 35288464)
21. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type.
Litwin V; Gumperz J; Parham P; Phillips JH; Lanier LL
J Exp Med; 1993 Oct; 178(4):1321-36. PubMed ID: 8376937
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection.
Li W; Zhu X; Xu Y; Chen J; Zhang H; Yang Z; Qi Y; Hong J; Li Y; Wang G; Shen J; Qian C
Front Immunol; 2022; 13():1052717. PubMed ID: 36532006
[TBL] [Abstract][Full Text] [Related]
23. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC
Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
25. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
26. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397
[TBL] [Abstract][Full Text] [Related]
27. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.
Elia AR; Circosta P; Sangiolo D; Bonini C; Gammaitoni L; Mastaglio S; Genovese P; Geuna M; Avolio F; Inghirami G; Tarella C; Cignetti A
Hum Gene Ther; 2015 Apr; 26(4):220-31. PubMed ID: 25758764
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.
Wu X; Shao Y; Tao Y; Ai G; Wei R; Meng X; Hou J; Han Y; Zhan F; Zheng J; Shi J
Biochem Biophys Res Commun; 2011 Nov; 415(1):187-92. PubMed ID: 22033416
[TBL] [Abstract][Full Text] [Related]
29. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.
Lo Monaco E; Tremante E; Cerboni C; Melucci E; Sibilio L; Zingoni A; Nicotra MR; Natali PG; Giacomini P
Neoplasia; 2011 Sep; 13(9):822-30. PubMed ID: 21969815
[TBL] [Abstract][Full Text] [Related]
30. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes.
Poggi A; Tomasello E; Revello V; Nanni L; Costa P; Moretta L
Int Immunol; 1997 Sep; 9(9):1271-9. PubMed ID: 9310830
[TBL] [Abstract][Full Text] [Related]
31. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
[TBL] [Abstract][Full Text] [Related]
32. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
34. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
35. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
36. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells.
Maddineni S; Silberstein JL; Sunwoo JB
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580928
[TBL] [Abstract][Full Text] [Related]
37. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
39. Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.
Gao M; Gao L; Yang G; Tao Y; Hou J; Xu H; Hu X; Han Y; Zhang Q; Zhan F; Wu X; Shi J
Acta Biochim Biophys Sin (Shanghai); 2014 Jul; 46(7):597-604. PubMed ID: 24850305
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte Colony-Stimulating Factor Effectively Mobilizes TCR γδ and NK Cells Providing an Allograft Potentially Enhanced for the Graft-Versus-Leukemia Effect for Allogeneic Stem Cell Transplantation.
Minculescu L; Sengelov H; Marquart HV; Ryder LP; Fischer-Nielsen A; Haastrup E
Front Immunol; 2021; 12():625165. PubMed ID: 33777007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
